Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: fujisaki s. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.
Ujike M, Ejima M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, Hong X, Takashita E, Fujisaki S, Yamashita K, Horikawa H, Kato Y, Oguchi A, Fujita N, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan. Ujike M, et al. Among authors: fujisaki s. Emerg Infect Dis. 2011 Mar;17(3):470-9. doi: 10.3201/eid1703.101188. Emerg Infect Dis. 2011. PMID: 21392439 Free PMC article.
Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.
Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, Yano T, Suga T, Kawakami C, Yamamoto M, Kajiyama K, Saito H, Shimada S, Watanabe S, Aoki S, Taira K, Kon M, Lin JH, Odagiri T. Kishida N, et al. Among authors: fujisaki s. Clin Vaccine Immunol. 2012 Jun;19(6):897-908. doi: 10.1128/CVI.05726-11. Epub 2012 Apr 4. Clin Vaccine Immunol. 2012. PMID: 22492743 Free PMC article.
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan. Takashita E, et al. Among authors: fujisaki s. Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8. Influenza Other Respir Viruses. 2013. PMID: 23745712 Free PMC article.
Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.
Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M. Takashita E, et al. Among authors: fujisaki s. Antimicrob Agents Chemother. 2015 May;59(5):2607-17. doi: 10.1128/AAC.04836-14. Epub 2015 Feb 17. Antimicrob Agents Chemother. 2015. PMID: 25691635 Free PMC article.
Characterization of an A (H1N1)pdm09 Virus Imported from India in March 2015.
Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Kuwahara T, Ohmiya S, Sato K, Ito H, Chiba F, Nishimura H, Shindo S, Watanabe S, Odagiri T; Influenza Virus Surveillance Group of Japan. Takashita E, et al. Among authors: fujisaki s. Jpn J Infect Dis. 2016;69(1):83-6. doi: 10.7883/yoken.JJID.2015.460. Epub 2015 Nov 13. Jpn J Infect Dis. 2016. PMID: 26567835 Free article. No abstract available.
421 results